Quest Diagnostics price target raised to $155 from $150 at Mizuho

Mizuho raised the firm’s price target on Quest Diagnostics to $155 from $150 and keeps a Buy rating on the shares. The analyst increased estimates following the “solid” Q1 results. The main takeaway from the results was that base business trends remain strong, benefiting from broad-based elevated utilization as well as share gain in the physician and hospital markets, the analyst tells investors in a research note.